TP53 and liver cancer: Combination treatment with BA and APO2 has been shown to inhibit liver cancer progression in vitro and in vivo by targeting the p53 signaling pathway, increasing apoptosis in APO2-resistant liver cancer cells without toxicity in normal cells or organs [40].